Contineum Therapeutics, Inc. Class A Common Stock - Asset Resilience Ratio
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has an Asset Resilience Ratio of 73.24% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Contineum Therapeutics, Inc. Class A Com carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Contineum Therapeutics, Inc. Class A Common Stock's Asset Resilience Ratio has changed over time. See Contineum Therapeutics, Inc. Class A Com shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Contineum Therapeutics, Inc. Class A Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Contineum Therapeutics, Inc. Class A Com stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $139.77 Million | 73.24% |
| Total Liquid Assets | $139.77 Million | 73.24% |
Asset Resilience Insights
- Very High Liquidity: Contineum Therapeutics, Inc. Class A Common Stock maintains exceptional liquid asset reserves at 73.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Contineum Therapeutics, Inc. Class A Common Stock Industry Peers by Asset Resilience Ratio
Compare Contineum Therapeutics, Inc. Class A Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Contineum Therapeutics, Inc. Class A Common Stock (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Contineum Therapeutics, Inc. Class A Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 85.89% | $182.82 Million | $212.85 Million | +1.78pp |
| 2023-12-31 | 84.11% | $109.66 Million | $130.39 Million | +1.81pp |
| 2022-12-31 | 82.29% | $41.67 Million | $50.64 Million | -8.99pp |
| 2021-12-31 | 91.29% | $64.37 Million | $70.52 Million | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idio… Read more